Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses
Listen to this summary
This study investigates how the number and timing of primary doses of the 20-valent pneumococcal conjugate vaccine (PCV20) affect immune responses in infants. The analysis reveals that a 1-month delay in the priming doses from 2 and 4 months to 3 and 5 months results in stronger immune responses, comparable to those elicited by the 13-valent vaccine (PCV13). Overall, PCV20 was found to be safe and well tolerated across different dosing schedules.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from The Pediatric infectious disease journal
View all →More in Pediatrics
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Critical care medicine
Ethical Implications of the Slow Code: A Systematic Review of Ethics of Slow Codes in U.S. Hospitals
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
